Abstract: The present invention relates to an oligopeptide and conjugates thereof. The present invention also relates to the use of these oligopeptide conjugates for treating or diagnosing disorders mediated by amyloid ? deposits. Finally, the present invention also relates to a coupling method for obtaining oligopeptide coupled with a substance of interest (functional conjugates).

Abstract: The present invention relates to variable domain of a camelid heavy-chain antibodies directed to amyloid ? and conjugates thereof. The present invention also relates to the use of these antibody conjugates for treating or diagnosing disorders mediated by amyloid ? deposits.

Abstract: An antibody binding to Tau that is phosphorylated at serine 422 (pS422), which specifically binds to phosphorylated Tau fragment of SEQ ID NO:9 and to Tau pS422, but does not bind to Tau and to phosphorylated MCAK fragment of SEQ ID NO:17. The antibody is useful in the treatment of a Tauopathy.

Abstract: The invention provides humanized anti-human Tau(pS422) antibodies and methods of using the same.

Abstract: The present invention provides an assay for the identification of beta-sheet aggregated protein ligands using Thiazine Red R.

Abstract: An antibody binding to Tau that is phosphorylated at serine 422 (pS422), which specifically binds to phosphorylated Tau fragment of SEQ ID NO:9 and to Tau pS422, but does not bind to Tau and to phosphorylated MCAK fragment of SEQ ID NO:17. The antibody is useful in the treatment of a Tauopathy.

Abstract: An antibody binding to Tau that is phosphorylated at serine 422 (pS422), which specifically binds to phosphorylated Tau fragment of SEQ ID NO:9 and to Tau pS422, but does not bind to Tau and to phosphorylated MCAK fragment of SEQ ID NO:17. The antibody is useful in the treatment of a Tauopathy.

Abstract: An antibody binding to Tau that is phosphorylated at serine 422 (pS422), which specifically binds to phosphorylated Tau fragment of SEQ ID NO:9 and to Tau pS422, but does not bind to Tau and to phosphorylated MCAK fragment of SEQ ID NO:17. The antibody is useful in the treatment of a Tauopathy.

Abstract: The present invention relates to an antibody which recognizes an epitope consisting of Ser-Ile-A1-A2-A3- A4-Ser(PO3H2)-Pro-Gln-Leu-Ala-Thr-Leu-Ala-A5 (SEQ ID NO: 9), and does not bind to an epitope consisting of Ser-Ile-A1-A2-A3- A4-Ser-Pro-Gln-Leu-Ala-Thr-Leu-Ala- A5 (SEQ ID NO: 8), wherein A1 is Asp or Asn, A2 is Met or Leu, A3 is Val or Leu, A4 is Asp or Glu and A5 is Asp or Glu, a hybridoma producing the antibody, a kit comprising the antibody, and a method for diagnosing a neurological disorder using the antibody.

Abstract: The present invention relates to an assay for identifying inhibitors of beta-secretases comprising the steps of immobilizing a beta-secretase protein on a solid support, contacting it with a test compound in the presence of a tagged beta-secretase inhibitor, and comparing the extent of binding of the tagged beta-secretase inhibitor in the presence and in the absence of the test compound in order to evaluate if the test compound is an inhibitor of beta-secretases. The present invention also relates to a method of screening for inhibitors of beta-secretases, to novel beta-secretase inhibitors and their use as tagged beta-secretase inhibitors for identification of inhibitors of beta-secetase, to a kit for identifying beta-secretase inhibiotrs as well as to novel beta-secretase inhibitors for use in the treatment of Alzheimer's disease and other cerebrovascular amyloidosis.